Allarity Q3 10-Q Flags Going-Concern Doubt and Nasdaq Equity Deficiency
ALLR sits 24% above its 52-week low of $0.769.
Summary
Allarity's Q3 2026 10-Q discloses substantial doubt about its ability to continue as a going concern and negative stockholders' equity that breaches Nasdaq's $2.5M minimum, with a post-quarter $3.0M debt-to-preferred conversion cited as restoring compliance.
Key Events · Earnings and Guidance · ALLR
-
Going-Concern Warning Disclosed
Management states substantial doubt about the company's ability to continue as a going concern within one year; $24.1M of cash and restricted cash as of September 30, 2026 may not fund operations for twelve months, and $10.0M of that is restricted as collateral for the B Note.
-
Negative Equity Breaches Nasdaq Rule
Stockholders' equity was $(2.3)M at September 30, 2026, below Nasdaq Capital Market Rule 5550(b)(1)'s $2.5M minimum; a deficiency notice could follow and require a compliance plan.
-
Losses and Interest Expense Widen
Q3 2026 net loss was $6.2M versus $2.8M a year earlier, and nine-month net loss $12.4M versus $7.9M; interest expense rose to $1.96M from $126K after the March 2026 Streeterville notes, which carried $21.6M at quarter-end.
-
R&D Jump on Phase 3 Manufacturing
Research and development expense rose to $4.2M in Q3 2026 from $1.2M, including a one-time $3.2M charge for Phase 3 drug manufacturing materials expensed at delivery.
Analysis · ALLR · Life Sciences
Allarity's Q3 report carries an explicit going-concern warning: with $24.1M of cash and restricted cash — $10.0M of which is locked up as collateral for the Streeterville B Note — management says it may not fund operations for the next twelve months. The company also ended the quarter with negative stockholders' equity of $(2.3)M, below Nasdaq's $2.5M continued-listing threshold, which puts a deficiency notice and potential delisting in play unless equity is rebuilt. Losses are widening ($12.4M for nine months versus $7.9M a year earlier) and interest expense has ballooned to $1.96M from $126K after the March 2026 $20M Streeterville financing. The one offset is a November 12, 2026 deal converting $3.0M of the A-1 Note into Series B Preferred Stock, which the company says pushes stockholders' equity back above $2.5M — a fix that trades debt for preferred equity rather than bringing in new cash.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ALLR was trading at $0.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.5M. The 52-week trading range was $0.77 to $1.84. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.